NEW BRUNSWICK, N.J.,
July 19, 2016 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today announced sales of
$18.5 billion for the second quarter
of 2016, an increase of 3.9% as compared to the second quarter of
2015. Operational sales results increased 5.3% and the negative
impact of currency was 1.4%. Domestic sales increased 7.4%.
International sales increased 0.4%, reflecting operational growth
of 3.1% and a negative currency impact of 2.7%. Excluding the net
impact of acquisitions, divestitures and hepatitis C sales, on an
operational basis, worldwide sales increased 7.9%, domestic sales
increased 8.8% and international sales increased
6.9%.* Operations in Venezuela negatively impacted worldwide
operational sales growth by 30 basis points, and international
sales growth by 70 basis points.
Net earnings and diluted earnings per share for the second
quarter of 2016 were $4.0 billion and
$1.43, respectively. Second
quarter 2016 net earnings included after-tax intangible
amortization expense of approximately $0.2
billion and a charge for after-tax special items of
approximately $0.7 billion. Second
quarter 2015 net earnings included after-tax intangible
amortization expense of approximately $0.2
billion and a charge for after-tax special items of
approximately $0.1 billion.
Excluding after-tax intangible amortization expense and special
items, adjusted net earnings for the current quarter were
$4.9 billion and adjusted diluted
earnings per share were $1.74,
representing increases of 1.1% and 1.8%, respectively, as compared
to the same period in 2015.* On an operational basis,
adjusted diluted earnings per share also increased
1.8%.* A reconciliation of non-GAAP financial
measures is included as an accompanying schedule.
"We continue to see good momentum through the first half of
2016, delivering solid results in the second quarter, supported by
strong underlying growth across our enterprise," said Alex Gorsky, Chairman and Chief Executive
Officer. "We saw notable strength in our Pharmaceuticals
business due to the continued success of new products, and also
achieved significant clinical milestones, advancing our robust
pipeline. In our Consumer business, we are executing strategic
portfolio decisions to expand our market leadership in key
segments, and in Medical Devices, we are continuing to accelerate
our growth driven by new product launches and transforming our
commercial models."
Mr. Gorsky continued, "I am proud of our dedicated and talented
employees whose commitment to advancing health and well-being for
patients and consumers around the world is fueling our growth."
The Company increased its sales guidance for the full-year 2016
to $71.5 billion to $72.2
billion. Additionally, the Company increased its
adjusted earnings guidance for full-year 2016 to $6.63 - $6.73 per share.*
Worldwide Consumer sales of $3.4
billion for the second quarter 2016 represented a decrease
of 1.8% versus the prior year, consisting of an operational
increase of 1.5% and a negative impact from currency of 3.3%.
Domestic sales increased 2.1%; international sales decreased 4.4%,
which reflected an operational increase of 1.0% and a negative
currency impact of 5.4%. Excluding the net impact of
acquisitions and divestitures, on an operational basis, worldwide
sales increased 3.9%, domestic sales increased 6.8% and
international sales increased 2.0%*. Operations in
Venezuela negatively impacted
worldwide Consumer operational sales growth by 120 basis points,
and international sales growth by 200 basis points.
Primary contributors to Consumer operational sales results were
NEUTROGENA® and AVEENO® skin care
products; over-the-counter products, including TYLENOL®
and MOTRIN® analgesics, digestive health products and
international anti-smoking aids; and LISTERINE® oral
care products.
During the quarter, the acquisitions of NeoStrata Company, Inc.,
a global leader in dermocosmetics, and the HIPOGLÓS®
diaper rash cream brand in Brazil
were completed. In addition, subsequent to the quarter, the
acquisition of Vogue International LLC, a privately-held company
focused on the marketing, development and distribution of
salon-influenced and nature inspired hair care and other personal
care products, was completed for $3.3
billion in cash.
Worldwide Pharmaceutical sales of $8.7
billion for the second quarter 2016 represented an increase
of 8.9% versus the prior year with an operational increase of 9.7%
and a negative impact from currency of 0.8%. Domestic sales
increased 13.2%; international sales increased 3.1%, which
reflected an operational increase of 4.9% and a negative currency
impact of 1.8%. Excluding the net impact of acquisitions,
divestitures and hepatitis C sales, on an operational basis,
worldwide sales increased 12.8%, domestic sales increased 13.9% and
international sales increased 11.2%.*
Worldwide operational sales growth was driven by new products
and the strength of core products. Strong growth in new products
include IMBRUVICA® (ibrutinib), an oral, once-daily
therapy approved for use in treating certain B-cell malignancies, a
type of blood or lymph node cancer; XARELTO®
(rivaroxaban), an oral anticoagulant; DARZALEX®
(daratumumab), for the treatment of patients with multiple myeloma;
INVOKANA®/INVOKAMET® (canagliflozin), for the
treatment of adults with type 2 diabetes; and ZYTIGA®
(abiraterone acetate), an oral, once-daily medication for use in
combination with prednisone for the treatment of metastatic,
castration-resistant prostate cancer. New product sales growth was
negatively impacted by lower sales of
OLYSIO®/SOVRIAD® (simeprevir) due to
competitive entrants.
Additional contributors to operational sales growth include
STELARA® (ustekinumab), a biologic approved for the
treatment of moderate to severe plaque psoriasis and psoriatic
arthritis; SIMPONI®/SIMPONI ARIA® (golimumab)
and REMICADE® (infliximab), biologics approved for the
treatment of a number of immune-mediated inflammatory diseases; and
INVEGA®
SUSTENNA®/XEPLION®/TRINZA®
(paliperidone palmitate), long-acting, injectable atypical
antipsychotics for the treatment of schizophrenia in adults.
During the quarter, the U.S. Food and Drug Administration (FDA)
approved an additional indication for INVOKAMET®
(canagliflozin/metformin HCl) for first-line treatment of adults
with type 2 diabetes and an expanded label for
IMBRUVICA® (ibrutinib) to include overall survival
and combination data in chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL). The European Commission (EC)
granted conditional approval to DARZALEX® (daratumumab)
for monotherapy of adult patients with relapsed and refractory
multiple myeloma and also approved IMBRUVICA®
(ibrutinib) for the treatment of adult patients with previously
untreated chronic lymphocytic leukemia, TREVICTA®
(paliperidone palmitate a 3 monthly injection) for the maintenance
treatment of schizophrenia in adult patients, and
SIMPONI® (golimumab) for the treatment of polyarticular
juvenile idiopathic arthritis.
In addition, the divestiture of the company's controlled
substance raw material and active pharmaceutical ingredient
business to SK Capital Partners, a private equity company, was
completed.
Worldwide Medical Devices sales of $6.4
billion for the second quarter 2016 represented an increase
of 0.8% versus the prior year consisting of an operational increase
of 1.8% and a negative currency impact of 1.0%. Domestic sales
increased 1.0%; international sales increased 0.6%, which reflected
an operational increase of 2.6% and a negative currency impact of
2.0%. Excluding the net impact of acquisitions and divestitures, on
an operational basis, worldwide sales increased 3.9%, domestic
sales increased 1.9% and international sales increased
5.8%.* Operations in Venezuela negatively impacted worldwide
operational sales growth by 30 basis points, and international
sales growth by 50 basis points.
Primary contributors to operational sales growth were
endocutters, energy and biosurgical products in the Advanced
Surgery business; electrophysiology products in the Cardiovascular
business; joint reconstruction and U.S. trauma products in
the Orthopaedics business; and ACUVUE® contact lenses in
the Vision Care business.
During the quarter, the acquisition of privately-held BioMedical
Enterprises, Inc., a leading manufacturer of Nitinol orthopaedic
implants for small bone fixation, was completed.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites
the people of Johnson & Johnson. We embrace research and
science - bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
126,500 employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
* Operational sales growth excluding the net impact
of acquisitions, divestitures and hepatitis C sales, as well as
adjusted net earnings, adjusted diluted earnings per share and
operational adjusted diluted earnings per share excluding after-tax
intangible amortization expense and special items, are non-GAAP
financial measures and should not be considered replacements for,
and should be read together with, the most comparable GAAP
financial measures. Except for guidance measures,
reconciliations of these non-GAAP financial measures to the most
directly comparable GAAP financial measures can be found in the
accompanying financial schedules of the earnings release and the
Investor Relations section of the company's website at
www.investor.jnj.com. Johnson & Johnson does not provide
GAAP financial measures on a forward-looking basis because the
company is unable to predict with reasonable certainty the ultimate
outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value
adjustments without unreasonable effort. These items are
uncertain, depend on various factors, and could be material to
Johnson & Johnson's results computed in accordance with
GAAP.
Johnson & Johnson will conduct a conference call with
investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast
of the call for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website at
www.investor.jnj.com. A replay and podcast will be available
approximately two hours after the live webcast by visiting
www.investor.jnj.com.
Copies of the financial schedules accompanying this press
release are available at www.investor.jnj.com/historical-sales.cfm.
These schedules include supplementary sales data, a condensed
consolidated statement of earnings, reconciliations of non-GAAP
financial measures, and sales of key products/franchises.
Additional information on Johnson & Johnson, including
adjusted income before tax by segment, a pharmaceutical pipeline of
selected compounds in late stage development and a copy of today's
earnings call presentation can be found on the company's website at
www.investor.jnj.com.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, future operating and financial
performance, product development, market position and business
strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to, economic factors, such as interest
rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success
for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the company to successfully
execute strategic plans, including restructuring plans; market
conditions and the possibility that the on-going share repurchase
program may be suspended or discontinued; the impact of business
combinations and divestitures; significant adverse litigation or
government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and
global health care reforms; trends toward health care cost
containment; changes in behavior and spending patterns or financial
distress of purchasers of health care products and services;
financial instability of international economies and legal systems
and sovereign risk; manufacturing difficulties or delays,
internally or within the supply chain; product efficacy or safety
concerns resulting in product recalls or regulatory action;
increased scrutiny of the health care industry by government
agencies; and the potential failure to meet obligations in
compliance agreements with government bodies. A further list and
description of these risks, uncertainties and other factors can be
found in Johnson & Johnson's Annual Report on Form 10-K for the
fiscal year ended January 3, 2016,
including in Exhibit 99 thereto, and the company's subsequent
filings with the Securities and Exchange Commission. Copies of
these filings are available online at www.sec.gov,
www.investor.jnj.com, or on request from Johnson & Johnson. Any
forward-looking statement made in this release speaks only as of
the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of
new information or future events or developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2016
|
|
2015
|
|
Total
|
|
Operations
|
Currency
|
|
2016
|
|
2015
|
|
Total
|
|
Operations
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,384
|
|
1,355
|
|
2.1
|
%
|
2.1
|
|
-
|
|
$
2,742
|
|
2,714
|
|
1.0
|
%
|
1.0
|
|
-
|
International
|
2,035
|
|
2,128
|
|
(4.4)
|
|
1.0
|
|
(5.4)
|
|
3,872
|
|
4,159
|
|
(6.9)
|
|
0.4
|
|
(7.3)
|
|
3,419
|
|
3,483
|
|
(1.8)
|
|
1.5
|
|
(3.3)
|
|
6,614
|
|
6,873
|
|
(3.8)
|
|
0.6
|
|
(4.4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
5,144
|
|
4,543
|
|
13.2
|
|
13.2
|
|
-
|
|
10,081
|
|
8,914
|
|
13.1
|
|
13.1
|
|
-
|
International
|
3,510
|
|
3,403
|
|
3.1
|
|
4.9
|
|
(1.8)
|
|
6,751
|
|
6,758
|
|
(0.1)
|
|
3.8
|
|
(3.9)
|
|
8,654
|
|
7,946
|
|
8.9
|
|
9.7
|
|
(0.8)
|
|
16,832
|
|
15,672
|
|
7.4
|
|
9.1
|
|
(1.7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,044
|
|
3,013
|
|
1.0
|
|
1.0
|
|
-
|
|
6,070
|
|
5,975
|
|
1.6
|
|
1.6
|
|
-
|
International
|
3,365
|
|
3,345
|
|
0.6
|
|
2.6
|
|
(2.0)
|
|
6,448
|
|
6,641
|
|
(2.9)
|
|
0.8
|
|
(3.7)
|
|
6,409
|
|
6,358
|
|
0.8
|
|
1.8
|
|
(1.0)
|
|
12,518
|
|
12,616
|
|
(0.8)
|
|
1.2
|
|
(2.0)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
9,572
|
|
8,911
|
|
7.4
|
|
7.4
|
|
-
|
|
18,893
|
|
17,603
|
|
7.3
|
|
7.3
|
|
-
|
International
|
8,910
|
|
8,876
|
|
0.4
|
|
3.1
|
|
(2.7)
|
|
17,071
|
|
17,558
|
|
(2.8)
|
|
1.8
|
|
(4.6)
|
Worldwide
|
$
18,482
|
|
17,787
|
|
3.9
|
%
|
5.3
|
|
(1.4)
|
|
$
35,964
|
|
35,161
|
|
2.3
|
%
|
4.6
|
|
(2.3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2016
|
|
2015
|
|
Total
|
|
Operations
|
Currency
|
|
2016
|
|
2015
|
|
Total
|
|
Operations
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
9,572
|
|
8,911
|
|
7.4
|
%
|
7.4
|
|
-
|
|
$
18,893
|
|
17,603
|
|
7.3
|
%
|
7.3
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
4,090
|
|
4,151
|
|
(1.5)
|
|
(0.6)
|
|
(0.9)
|
|
7,937
|
|
8,191
|
|
(3.1)
|
|
(0.6)
|
|
(2.5)
|
Western Hemisphere
excluding U.S.
|
1,542
|
|
1,501
|
|
2.7
|
|
15.4
|
|
(12.7)
|
|
2,873
|
|
3,140
|
|
(8.5)
|
|
7.1
|
|
(15.6)
|
Asia-Pacific,
Africa
|
3,278
|
|
3,224
|
|
1.7
|
|
2.1
|
|
(0.4)
|
|
6,261
|
|
6,227
|
|
0.5
|
|
2.5
|
|
(2.0)
|
International
|
8,910
|
|
8,876
|
|
0.4
|
|
3.1
|
|
(2.7)
|
|
17,071
|
|
17,558
|
|
(2.8)
|
|
1.8
|
|
(4.6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
18,482
|
|
17,787
|
|
3.9
|
%
|
5.3
|
|
(1.4)
|
|
$
35,964
|
|
35,161
|
|
2.3
|
%
|
4.6
|
|
(2.3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
SECOND
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2016
|
|
2015
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
18,482
|
|
100.0
|
|
$
17,787
|
|
100.0
|
|
3.9
|
Cost of products
sold
|
5,336
|
|
28.9
|
|
5,357
|
|
30.1
|
|
(0.4)
|
Selling, marketing
and administrative expenses
|
5,176
|
|
28.0
|
|
5,384
|
|
30.3
|
|
(3.9)
|
Research and
development expense
|
2,264
|
|
12.2
|
|
2,129
|
|
12.0
|
|
6.3
|
In-process
research and development
|
29
|
|
0.2
|
|
-
|
|
-
|
|
|
Interest (income)
expense, net
|
102
|
|
0.6
|
|
107
|
|
0.6
|
|
|
Other (income)
expense, net
|
557
|
|
3.0
|
|
(931)
|
|
(5.3)
|
|
|
Restructuring
|
114
|
|
0.6
|
|
-
|
|
-
|
|
|
Earnings before
provision for taxes on income
|
4,904
|
|
26.5
|
|
5,741
|
|
32.3
|
|
(14.6)
|
Provision for
taxes on income
|
907
|
|
4.9
|
|
1,225
|
|
6.9
|
|
(26.0)
|
Net
earnings
|
$
3,997
|
|
21.6
|
|
$
4,516
|
|
25.4
|
|
(11.5)
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.43
|
|
|
|
$
1.61
|
|
|
|
(11.2)
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,794.2
|
|
|
|
2,812.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
18.5
|
%
|
|
|
21.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings
before provision for taxes on income
|
$
6,024
|
|
32.6
|
|
$
6,248
|
|
35.1
|
|
(3.6)
|
Net
earnings
|
$
4,866
|
|
26.3
|
|
$
4,812
|
|
27.1
|
|
1.1
|
Net earnings
per share (Diluted)
|
$
1.74
|
|
|
|
$
1.71
|
|
|
|
1.8
|
Effective
tax rate
|
19.2
|
%
|
|
|
23.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
SIX
MONTHS
|
|
|
|
|
|
|
|
|
|
|
|
2016
|
|
2015
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
35,964
|
|
100.0
|
|
$
35,161
|
|
100.0
|
|
2.3
|
Cost of products
sold
|
10,665
|
|
29.6
|
|
10,639
|
|
30.2
|
|
0.2
|
Selling, marketing
and administrative expenses
|
9,864
|
|
27.4
|
|
10,231
|
|
29.1
|
|
(3.6)
|
Research and
development expense
|
4,277
|
|
11.9
|
|
4,028
|
|
11.5
|
|
6.2
|
In-process
research and development
|
29
|
|
0.1
|
|
-
|
|
-
|
|
|
Interest (income)
expense, net
|
179
|
|
0.5
|
|
226
|
|
0.6
|
|
|
Other (income)
expense, net
|
518
|
|
1.4
|
|
(1,279)
|
|
(3.6)
|
|
|
Restructuring
|
234
|
|
0.7
|
|
-
|
|
-
|
|
|
Earnings before
provision for taxes on income
|
10,198
|
|
28.4
|
|
11,316
|
|
32.2
|
|
(9.9)
|
Provision for
taxes on income
|
1,744
|
|
4.9
|
|
2,480
|
|
7.1
|
|
(29.7)
|
Net
earnings
|
$
8,454
|
|
23.5
|
|
$
8,836
|
|
25.1
|
|
(4.3)
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
3.02
|
|
|
|
$
3.13
|
|
|
|
(3.5)
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,800.9
|
|
|
|
2,821.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
17.1
|
%
|
|
|
21.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings
before provision for taxes on income
|
$
11,825
|
|
32.9
|
|
$
11,878
|
|
33.8
|
|
(0.4)
|
Net
earnings
|
$
9,720
|
|
27.0
|
|
$
9,230
|
|
26.3
|
|
5.3
|
Net earnings
per share (Diluted)
|
$
3.47
|
|
|
|
$
3.27
|
|
|
|
6.1
|
Effective
tax rate
|
17.8
|
%
|
|
|
22.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second
Quarter
|
|
% Incr. /
|
|
|
Six Months
YTD
|
|
% Incr. /
|
|
(Dollars in
Millions Except Per Share Data)
|
|
2016
|
|
2015
|
|
(Decr.)
|
|
|
2016
|
|
2015
|
|
(Decr.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as reported
|
|
$ 4,904
|
|
5,741
|
|
(14.6)
|
%
|
|
$ 10,198
|
|
11,316
|
|
(9.9)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
|
326
|
|
318
|
|
|
|
|
608
|
|
630
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
(1)
|
|
141
|
|
-
|
|
|
|
|
278
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation
expense/(gain), net
|
|
600
|
|
134
|
|
|
|
|
666
|
|
(268)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
|
-
|
|
9
|
|
|
|
|
-
|
|
148
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
|
29
|
|
-
|
|
|
|
|
29
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
24
|
|
46
|
|
|
|
|
46
|
|
52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as adjusted
|
|
$ 6,024
|
|
6,248
|
|
(3.6)
|
%
|
|
$ 11,825
|
|
11,878
|
|
(0.4)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
reported
|
|
$ 3,997
|
|
4,516
|
|
(11.5)
|
%
|
|
$
8,454
|
|
8,836
|
|
(4.3)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
|
238
|
|
230
|
|
|
|
|
443
|
|
456
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
|
|
97
|
|
-
|
|
|
|
|
217
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation
expense/(gain), net
|
|
493
|
|
23
|
|
|
|
|
549
|
|
(230)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
|
-
|
|
8
|
|
|
|
|
-
|
|
130
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
|
23
|
|
-
|
|
|
|
|
23
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
18
|
|
35
|
|
|
|
|
34
|
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
adjusted
|
|
$ 4,866
|
|
4,812
|
|
1.1
|
%
|
|
$
9,720
|
|
9,230
|
|
5.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as reported
|
|
$
1.43
|
|
1.61
|
|
(11.2)
|
%
|
|
$
3.02
|
|
3.13
|
|
(3.5)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
|
0.08
|
|
0.08
|
|
|
|
|
0.16
|
|
0.16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
|
|
0.03
|
|
-
|
|
|
|
|
0.08
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation
expense/(gain), net
|
|
0.18
|
|
0.01
|
|
|
|
|
0.19
|
|
(0.08)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DePuy ASR™ Hip program
|
|
-
|
|
-
|
|
|
|
|
-
|
|
0.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
|
0.01
|
|
-
|
|
|
|
|
0.01
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
0.01
|
|
0.01
|
|
|
|
|
0.01
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as adjusted
|
|
$
1.74
|
|
1.71
|
|
1.8
|
%
|
|
$
3.47
|
|
3.27
|
|
6.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted at 2014 foreign currency
exchange rates
|
|
|
|
1.90
|
|
|
|
|
|
|
3.59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of currency at
2015 foreign currency exchange rates
|
|
$
-
|
|
(0.19)
|
|
|
|
|
$
0.04
|
|
(0.32)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted at 2015 foreign currency
exchange rates
|
|
$
1.74
|
|
1.71
|
|
1.8
|
%
|
|
$
3.51
|
|
3.27
|
|
7.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
Includes $7M recorded in cost of products sold and $20M recorded in
other (income) expense for the second quarter.
|
|
|
|
|
|
|
|
|
Includes $24M recorded in
cost of products sold and $20M recorded in other (income) expense
for six months YTD.
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales
(1)
|
SECOND
QUARTER 2016 ACTUAL vs. 2015 ACTUAL
|
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational %
(2)
|
WW As
Reported:
|
|
1.5%
|
|
9.7%
|
|
1.8%
|
|
5.3%
|
U.S.
|
|
2.1%
|
|
13.2%
|
|
1.0%
|
|
7.4%
|
International
|
|
1.0%
|
|
4.9%
|
|
2.6%
|
|
3.1%
|
|
|
|
|
|
|
|
|
|
Wound
Care/Other
|
|
|
|
|
|
|
|
|
SPLENDA®
|
|
2.5
|
|
|
|
|
|
0.5
|
U.S.
|
|
4.9
|
|
|
|
|
|
0.7
|
International
|
|
1.0
|
|
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
Cardiovascular
|
|
|
|
|
|
|
|
|
Cordis
|
|
|
|
|
|
2.3
|
|
0.8
|
U.S.
|
|
|
|
|
|
1.1
|
|
0.4
|
International
|
|
|
|
|
|
3.5
|
|
1.3
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
(0.1)
|
|
(0.1)
|
|
(0.2)
|
|
(0.1)
|
U.S.
|
|
(0.2)
|
|
(0.1)
|
|
(0.2)
|
|
(0.1)
|
International
|
|
0.0
|
|
0.0
|
|
(0.3)
|
|
(0.1)
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
3.9%
|
|
9.6%
|
|
3.9%
|
|
6.5%
|
U.S.
|
|
6.8%
|
|
13.1%
|
|
1.9%
|
|
8.4%
|
International
|
|
2.0%
|
|
4.9%
|
|
5.8%
|
|
4.5%
|
|
|
|
|
|
|
|
|
|
Hepatitis
C
|
|
|
|
3.2
|
|
|
|
1.4
|
U.S.
|
|
|
|
0.8
|
|
|
|
0.4
|
International
|
|
|
|
6.3
|
|
|
|
2.4
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Hepatitis C only
|
|
|
|
12.9%
|
|
|
|
6.7%
|
U.S.
|
|
|
|
14.0%
|
|
|
|
7.8%
|
International
|
|
|
|
11.2%
|
|
|
|
5.5%
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions, Divestitures and Hepatitis C
|
|
3.9%
|
|
12.8%
|
|
3.9%
|
|
7.9%
|
U.S.
|
|
6.8%
|
|
13.9%
|
|
1.9%
|
|
8.8%
|
International
|
|
2.0%
|
|
11.2%
|
|
5.8%
|
|
6.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
Hepatitis C products include OLYSIO ®/SOVRIAD
®and INCIVO ®
|
|
|
|
|
|
|
|
|
(2)
Operational growth excludes the effect of translational
currency
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales
(1)
|
SIX MONTHS
2016 ACTUAL vs. 2015 ACTUAL
|
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational %
(2)
|
WW As
Reported:
|
|
0.6%
|
|
9.1%
|
|
1.2%
|
|
4.6%
|
U.S.
|
|
1.0%
|
|
13.1%
|
|
1.6%
|
|
7.3%
|
International
|
|
0.4%
|
|
3.8%
|
|
0.8%
|
|
1.8%
|
|
|
|
|
|
|
|
|
|
Wound
Care/Other
|
|
|
|
|
|
|
|
|
SPLENDA®
|
|
2.3
|
|
|
|
|
|
0.4
|
U.S.
|
|
4.5
|
|
|
|
|
|
0.7
|
International
|
|
0.8
|
|
|
|
|
|
0.2
|
|
|
|
|
|
|
|
|
|
Cardiovascular
|
|
|
|
|
|
|
|
|
Cordis
|
|
|
|
|
|
2.3
|
|
0.9
|
U.S.
|
|
|
|
|
|
1.1
|
|
0.4
|
International
|
|
|
|
|
|
3.5
|
|
1.4
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.0
|
|
0.2
|
|
(0.1)
|
|
0.1
|
U.S.
|
|
(0.1)
|
|
0.4
|
|
(0.1)
|
|
0.2
|
International
|
|
0.1
|
|
0.0
|
|
0.0
|
|
0.0
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
2.9%
|
|
9.3%
|
|
3.4%
|
|
6.0%
|
U.S.
|
|
5.4%
|
|
13.5%
|
|
2.6%
|
|
8.6%
|
International
|
|
1.3%
|
|
3.8%
|
|
4.3%
|
|
3.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hepatitis
C
|
|
|
|
3.2
|
|
|
|
1.4
|
U.S.
|
|
|
|
1.5
|
|
|
|
0.7
|
International
|
|
|
|
5.4
|
|
|
|
2.0
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Hepatitis C only
|
|
|
|
12.3%
|
|
|
|
6.0%
|
U.S.
|
|
|
|
14.6%
|
|
|
|
8.0%
|
International
|
|
|
|
9.2%
|
|
|
|
3.8%
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions, Divestitures, and Hepatitis C
|
|
2.9%
|
|
12.5%
|
|
3.4%
|
|
7.4%
|
U.S.
|
|
5.4%
|
|
15.0%
|
|
2.6%
|
|
9.3%
|
International
|
|
1.3%
|
|
9.2%
|
|
4.3%
|
|
5.4%
|
|
|
|
|
|
|
|
|
|
(1)
Hepatitis C products include OLYSIO ®/SOVRIAD
®and INCIVO ®
|
|
|
|
|
|
|
|
|
(2)
Operational growth excludes the effect of translational
currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER SEGMENT
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BABY CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
102
|
|
104
|
-1.9%
|
-1.9%
|
-
|
|
|
$
197
|
|
215
|
-8.4%
|
-8.4%
|
-
|
Intl
|
|
398
|
|
439
|
-9.3%
|
-2.2%
|
-7.1%
|
|
|
754
|
|
839
|
-10.1%
|
-1.1%
|
-9.0%
|
WW
|
|
500
|
|
543
|
-7.9%
|
-2.1%
|
-5.8%
|
|
|
951
|
|
1,054
|
-9.8%
|
-2.6%
|
-7.2%
|
ORAL CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
159
|
|
147
|
8.2%
|
8.2%
|
-
|
|
|
329
|
|
305
|
7.9%
|
7.9%
|
-
|
Intl
|
|
244
|
|
244
|
0.0%
|
5.6%
|
-5.6%
|
|
|
459
|
|
489
|
-6.1%
|
1.3%
|
-7.4%
|
WW
|
|
403
|
|
391
|
3.1%
|
6.6%
|
-3.5%
|
|
|
788
|
|
794
|
-0.8%
|
3.8%
|
-4.6%
|
OTC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
389
|
|
366
|
6.3%
|
6.3%
|
-
|
|
|
850
|
|
771
|
10.2%
|
10.2%
|
-
|
Intl
|
|
619
|
|
608
|
1.8%
|
6.1%
|
-4.3%
|
|
|
1,177
|
|
1,196
|
-1.6%
|
4.5%
|
-6.1%
|
WW
|
|
1,008
|
|
974
|
3.5%
|
6.2%
|
-2.7%
|
|
|
2,027
|
|
1,967
|
3.1%
|
6.8%
|
-3.7%
|
SKIN CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
555
|
|
491
|
13.0%
|
13.0%
|
-
|
|
|
1,043
|
|
983
|
6.1%
|
6.1%
|
-
|
Intl
|
|
398
|
|
403
|
-1.2%
|
3.5%
|
-4.7%
|
|
|
772
|
|
814
|
-5.2%
|
1.3%
|
-6.5%
|
WW
|
|
953
|
|
894
|
6.6%
|
8.7%
|
-2.1%
|
|
|
1,815
|
|
1,797
|
1.0%
|
3.9%
|
-2.9%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
7
|
|
7
|
0.0%
|
0.0%
|
-
|
|
|
13
|
|
13
|
0.0%
|
0.0%
|
-
|
Intl
|
|
276
|
|
313
|
-11.8%
|
-4.8%
|
-7.0%
|
|
|
521
|
|
594
|
-12.3%
|
-3.0%
|
-9.3%
|
WW
|
|
283
|
|
320
|
-11.6%
|
-4.8%
|
-6.8%
|
|
|
534
|
|
607
|
-12.0%
|
-2.9%
|
-9.1%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
172
|
|
240
|
-28.3%
|
-28.3%
|
-
|
|
|
310
|
|
427
|
-27.4%
|
-27.4%
|
-
|
Intl
|
|
100
|
|
121
|
-17.4%
|
-14.2%
|
-3.2%
|
|
|
189
|
|
227
|
-16.7%
|
-11.4%
|
-5.3%
|
WW
|
|
272
|
|
361
|
-24.7%
|
-23.6%
|
-1.1%
|
|
|
499
|
|
654
|
-23.7%
|
-21.9%
|
-1.8%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
CONSUMER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,384
|
|
1,355
|
2.1%
|
2.1%
|
-
|
|
|
2,742
|
|
2,714
|
1.0%
|
1.0%
|
-
|
Intl
|
|
2,035
|
|
2,128
|
-4.4%
|
1.0%
|
-5.4%
|
|
|
3,872
|
|
4,159
|
-6.9%
|
0.4%
|
-7.3%
|
WW
|
|
$
3,419
|
|
3,483
|
-1.8%
|
1.5%
|
-3.3%
|
|
|
$
6,614
|
|
6,873
|
-3.8%
|
0.6%
|
-4.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
PHARMACEUTICAL
SEGMENT (2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
2,224
|
|
1,876
|
18.6%
|
18.6%
|
-
|
|
|
$
4,395
|
|
3,631
|
21.0%
|
21.0%
|
-
|
Intl
|
|
814
|
|
678
|
20.1%
|
23.0%
|
-2.9%
|
|
|
1,553
|
|
1,386
|
12.0%
|
17.7%
|
-5.7%
|
WW
|
|
3,038
|
|
2,554
|
19.0%
|
19.8%
|
-0.8%
|
|
|
5,948
|
|
5,017
|
18.6%
|
20.2%
|
-1.6%
|
REMICADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,236
|
|
1,088
|
13.6%
|
13.6%
|
-
|
|
|
2,447
|
|
2,143
|
14.2%
|
14.2%
|
-
|
US Exports
(3)
|
|
185
|
|
241
|
-23.2%
|
-23.2%
|
-
|
|
|
418
|
|
422
|
-0.9%
|
-0.9%
|
-
|
Intl
|
|
359
|
|
339
|
5.9%
|
11.1%
|
-5.2%
|
|
|
694
|
|
703
|
-1.3%
|
6.2%
|
-7.5%
|
WW
|
|
1,780
|
|
1,668
|
6.7%
|
7.7%
|
-1.0%
|
|
|
3,559
|
|
3,268
|
8.9%
|
10.5%
|
-1.6%
|
SIMPONI /
SIMPONI ARIA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
244
|
|
172
|
41.9%
|
41.9%
|
-
|
|
|
460
|
|
327
|
40.7%
|
40.7%
|
-
|
Intl
|
|
204
|
|
136
|
50.0%
|
49.7%
|
0.3%
|
|
|
378
|
|
281
|
34.5%
|
38.3%
|
-3.8%
|
WW
|
|
448
|
|
308
|
45.5%
|
45.4%
|
0.1%
|
|
|
838
|
|
608
|
37.8%
|
39.5%
|
-1.7%
|
STELARA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
559
|
|
375
|
49.1%
|
49.1%
|
-
|
|
|
1,070
|
|
739
|
44.8%
|
44.8%
|
-
|
Intl
|
|
245
|
|
195
|
25.6%
|
26.4%
|
-0.8%
|
|
|
469
|
|
380
|
23.4%
|
26.8%
|
-3.4%
|
WW
|
|
804
|
|
570
|
41.1%
|
41.4%
|
-0.3%
|
|
|
1,539
|
|
1,119
|
37.5%
|
38.7%
|
-1.2%
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
6
|
|
8
|
-25.0%
|
-15.2%
|
-9.8%
|
|
|
12
|
|
22
|
-45.5%
|
-36.4%
|
-9.1%
|
WW
|
|
6
|
|
8
|
-25.0%
|
-15.2%
|
-9.8%
|
|
|
12
|
|
22
|
-45.5%
|
-36.4%
|
-9.1%
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
362
|
|
381
|
-5.0%
|
-5.0%
|
-
|
|
|
720
|
|
793
|
-9.2%
|
-9.2%
|
-
|
Intl
|
|
467
|
|
651
|
-28.3%
|
-27.3%
|
-1.0%
|
|
|
885
|
|
1,214
|
-27.1%
|
-24.8%
|
-2.3%
|
WW
|
|
829
|
|
1,032
|
-19.7%
|
-19.1%
|
-0.6%
|
|
|
1,605
|
|
2,007
|
-20.0%
|
-18.6%
|
-1.4%
|
EDURANT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
14
|
|
9
|
55.6%
|
55.6%
|
-
|
|
|
25
|
|
18
|
38.9%
|
38.9%
|
-
|
Intl
|
|
126
|
|
92
|
37.0%
|
35.1%
|
1.9%
|
|
|
234
|
|
174
|
34.5%
|
35.2%
|
-0.7%
|
WW
|
|
140
|
|
101
|
38.6%
|
36.9%
|
1.7%
|
|
|
259
|
|
192
|
34.9%
|
35.6%
|
-0.7%
|
OLYSIO /
SOVRIAD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
21
|
|
50
|
-58.0%
|
-58.0%
|
-
|
|
|
37
|
|
148
|
-75.0%
|
-75.0%
|
-
|
Intl
|
|
22
|
|
214
|
-89.7%
|
-89.4%
|
-0.3%
|
|
|
38
|
|
350
|
-89.1%
|
-88.5%
|
-0.6%
|
WW
|
|
43
|
|
264
|
-83.7%
|
-83.5%
|
-0.2%
|
|
|
75
|
|
498
|
-84.9%
|
-84.5%
|
-0.4%
|
PREZISTA /
PREZCOBIX / REZOLSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
273
|
|
258
|
5.8%
|
5.8%
|
-
|
|
|
550
|
|
492
|
11.8%
|
11.8%
|
-
|
Intl
|
|
186
|
|
190
|
-2.1%
|
-0.6%
|
-1.5%
|
|
|
361
|
|
383
|
-5.7%
|
-2.6%
|
-3.1%
|
WW
|
|
459
|
|
448
|
2.5%
|
3.1%
|
-0.6%
|
|
|
911
|
|
875
|
4.1%
|
5.5%
|
-1.4%
|
OTHER
INFECTIOUS DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
54
|
|
64
|
-15.6%
|
-15.6%
|
-
|
|
|
108
|
|
135
|
-20.0%
|
-20.0%
|
-
|
Intl
|
|
133
|
|
155
|
-14.2%
|
-11.2%
|
-3.0%
|
|
|
252
|
|
307
|
-17.9%
|
-13.9%
|
-4.0%
|
WW
|
|
187
|
|
219
|
-14.6%
|
-12.5%
|
-2.1%
|
|
|
360
|
|
442
|
-18.6%
|
-15.8%
|
-2.8%
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
695
|
|
693
|
0.3%
|
0.3%
|
-
|
|
|
1,375
|
|
1,443
|
-4.7%
|
-4.7%
|
-
|
Intl
|
|
907
|
|
871
|
4.1%
|
4.7%
|
-0.6%
|
|
|
1,776
|
|
1,739
|
2.1%
|
5.1%
|
-3.0%
|
WW
|
|
1,602
|
|
1,564
|
2.4%
|
2.8%
|
-0.4%
|
|
|
3,151
|
|
3,182
|
-1.0%
|
0.6%
|
-1.6%
|
CONCERTA /
METHYLPHENIDATE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
129
|
|
102
|
26.5%
|
26.5%
|
-
|
|
|
263
|
|
228
|
15.4%
|
15.4%
|
-
|
Intl
|
|
109
|
|
104
|
4.8%
|
8.4%
|
-3.6%
|
|
|
206
|
|
202
|
2.0%
|
7.4%
|
-5.4%
|
WW
|
|
238
|
|
206
|
15.5%
|
17.3%
|
-1.8%
|
|
|
469
|
|
430
|
9.1%
|
11.7%
|
-2.6%
|
INVEGA /
PALIPERIDONE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
18
|
|
105
|
-82.9%
|
-82.9%
|
-
|
|
|
42
|
|
199
|
-78.9%
|
-78.9%
|
-
|
Intl
|
|
64
|
|
61
|
4.9%
|
3.4%
|
1.5%
|
|
|
126
|
|
122
|
3.3%
|
4.4%
|
-1.1%
|
WW
|
|
82
|
|
166
|
-50.6%
|
-51.2%
|
0.6%
|
|
|
168
|
|
321
|
-47.7%
|
-47.3%
|
-0.4%
|
INVEGA SUSTENNA
/ XEPLION / INVEGA TRINZA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
339
|
|
253
|
34.0%
|
34.0%
|
-
|
|
|
644
|
|
481
|
33.9%
|
33.9%
|
-
|
Intl
|
|
221
|
|
183
|
20.8%
|
21.2%
|
-0.4%
|
|
|
429
|
|
366
|
17.2%
|
20.2%
|
-3.0%
|
WW
|
|
560
|
|
436
|
28.4%
|
28.6%
|
-0.2%
|
|
|
1,073
|
|
847
|
26.7%
|
28.0%
|
-1.3%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
100
|
|
99
|
1.0%
|
1.0%
|
-
|
|
|
195
|
|
203
|
-3.9%
|
-3.9%
|
-
|
Intl
|
|
130
|
|
148
|
-12.2%
|
-11.9%
|
-0.3%
|
|
|
266
|
|
298
|
-10.7%
|
-8.4%
|
-2.3%
|
WW
|
|
230
|
|
247
|
-6.9%
|
-6.7%
|
-0.2%
|
|
|
461
|
|
501
|
-8.0%
|
-6.6%
|
-1.4%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
109
|
|
134
|
-18.7%
|
-18.7%
|
-
|
|
|
231
|
|
332
|
-30.4%
|
-30.4%
|
-
|
Intl
|
|
383
|
|
375
|
2.1%
|
2.6%
|
-0.5%
|
|
|
749
|
|
751
|
-0.3%
|
2.6%
|
-2.9%
|
WW
|
|
492
|
|
509
|
-3.3%
|
-3.0%
|
-0.3%
|
|
|
980
|
|
1,083
|
-9.5%
|
-7.5%
|
-2.0%
|
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
569
|
|
362
|
57.2%
|
57.2%
|
-
|
|
|
1,118
|
|
696
|
60.6%
|
60.6%
|
-
|
Intl
|
|
905
|
|
782
|
15.7%
|
17.1%
|
-1.4%
|
|
|
1,710
|
|
1,556
|
9.9%
|
13.5%
|
-3.6%
|
WW
|
|
1,474
|
|
1,144
|
28.8%
|
29.8%
|
-1.0%
|
|
|
2,828
|
|
2,252
|
25.6%
|
28.1%
|
-2.5%
|
IMBRUVICA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
144
|
|
89
|
61.8%
|
61.8%
|
-
|
|
|
276
|
|
155
|
78.1%
|
78.1%
|
-
|
Intl
|
|
151
|
|
65
|
*
|
*
|
**
|
|
|
280
|
|
115
|
*
|
*
|
**
|
WW
|
|
295
|
|
154
|
91.6%
|
93.1%
|
-1.5%
|
|
|
556
|
|
270
|
*
|
*
|
**
|
VELCADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
342
|
|
344
|
-0.6%
|
1.4%
|
-2.0%
|
|
|
646
|
|
683
|
-5.4%
|
-2.0%
|
-3.4%
|
WW
|
|
342
|
|
344
|
-0.6%
|
1.4%
|
-2.0%
|
|
|
646
|
|
683
|
-5.4%
|
-2.0%
|
-3.4%
|
ZYTIGA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
286
|
|
255
|
12.2%
|
12.2%
|
-
|
|
|
558
|
|
508
|
9.8%
|
9.8%
|
-
|
Intl
|
|
315
|
|
291
|
8.2%
|
8.4%
|
-0.2%
|
|
|
601
|
|
594
|
1.2%
|
4.1%
|
-2.9%
|
WW
|
|
601
|
|
546
|
10.1%
|
10.2%
|
-0.1%
|
|
|
1,159
|
|
1,102
|
5.2%
|
6.8%
|
-1.6%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
139
|
|
18
|
*
|
*
|
-
|
|
|
284
|
|
33
|
*
|
*
|
-
|
Intl
|
|
97
|
|
82
|
18.3%
|
20.1%
|
-1.8%
|
|
|
183
|
|
164
|
11.6%
|
15.6%
|
-4.0%
|
WW
|
|
236
|
|
100
|
*
|
*
|
**
|
|
|
467
|
|
197
|
*
|
*
|
**
|
CARDIOVASCULAR /
METABOLISM / OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,294
|
|
1,231
|
5.1%
|
5.1%
|
-
|
|
|
2,473
|
|
2,351
|
5.2%
|
5.2%
|
-
|
Intl
|
|
417
|
|
421
|
-1.0%
|
3.2%
|
-4.2%
|
|
|
827
|
|
863
|
-4.2%
|
1.4%
|
-5.6%
|
WW
|
|
1,711
|
|
1,652
|
3.6%
|
4.7%
|
-1.1%
|
|
|
3,300
|
|
3,214
|
2.7%
|
4.2%
|
-1.5%
|
XARELTO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
594
|
|
472
|
25.8%
|
25.8%
|
-
|
|
|
1,161
|
|
913
|
27.2%
|
27.2%
|
-
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
WW
|
|
594
|
|
472
|
25.8%
|
25.8%
|
-
|
|
|
1,161
|
|
913
|
27.2%
|
27.2%
|
-
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
348
|
|
302
|
15.2%
|
15.2%
|
-
|
|
|
645
|
|
568
|
13.6%
|
13.6%
|
-
|
Intl
|
|
35
|
|
16
|
*
|
*
|
**
|
|
|
63
|
|
28
|
*
|
*
|
**
|
WW
|
|
383
|
|
318
|
20.4%
|
21.0%
|
-0.6%
|
|
|
708
|
|
596
|
18.8%
|
19.5%
|
-0.7%
|
PROCRIT /
EPREX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
230
|
|
179
|
28.5%
|
28.5%
|
-
|
|
|
413
|
|
342
|
20.8%
|
20.8%
|
-
|
Intl
|
|
92
|
|
97
|
-5.2%
|
-2.9%
|
-2.3%
|
|
|
183
|
|
203
|
-9.9%
|
-5.9%
|
-4.0%
|
WW
|
|
322
|
|
276
|
16.7%
|
17.5%
|
-0.8%
|
|
|
596
|
|
545
|
9.4%
|
10.9%
|
-1.5%
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
122
|
|
278
|
-56.1%
|
-56.1%
|
-
|
|
|
254
|
|
528
|
-51.9%
|
-51.9%
|
-
|
Intl
|
|
290
|
|
308
|
-5.8%
|
-1.4%
|
-4.4%
|
|
|
581
|
|
632
|
-8.1%
|
-2.5%
|
-5.6%
|
WW
|
|
412
|
|
586
|
-29.7%
|
-27.4%
|
-2.3%
|
|
|
835
|
|
1,160
|
-28.0%
|
-25.0%
|
-3.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
5,144
|
|
4,543
|
13.2%
|
13.2%
|
-
|
|
|
10,081
|
|
8,914
|
13.1%
|
13.1%
|
-
|
Intl
|
|
3,510
|
|
3,403
|
3.1%
|
4.9%
|
-1.8%
|
|
|
6,751
|
|
6,758
|
-0.1%
|
3.8%
|
-3.9%
|
WW
|
|
$
8,654
|
|
7,946
|
8.9%
|
9.7%
|
-0.8%
|
|
|
$
16,832
|
|
15,672
|
7.4%
|
9.1%
|
-1.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
SECOND
QUARTER
|
|
SIX
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2016
|
|
2015
|
Reported
|
Operational
(1)
|
Currency
|
MEDICAL DEVICES
SEGMENT (2) (4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CARDIOVASCULAR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
235
|
|
235
|
0.0%
|
0.0%
|
-
|
|
|
$
466
|
|
463
|
0.6%
|
0.6%
|
-
|
Intl
|
|
235
|
|
309
|
-23.9%
|
-23.8%
|
-0.1%
|
|
|
447
|
|
610
|
-26.7%
|
-25.0%
|
-1.7%
|
WW
|
|
470
|
|
544
|
-13.6%
|
-13.6%
|
0.0%
|
|
|
913
|
|
1,073
|
-14.9%
|
-14.0%
|
-0.9%
|
DIABETES
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
177
|
|
214
|
-17.3%
|
-17.3%
|
-
|
|
|
357
|
|
426
|
-16.2%
|
-16.2%
|
-
|
Intl
|
|
294
|
|
280
|
5.0%
|
7.0%
|
-2.0%
|
|
|
543
|
|
552
|
-1.6%
|
2.2%
|
-3.8%
|
WW
|
|
471
|
|
494
|
-4.7%
|
-3.5%
|
-1.2%
|
|
|
900
|
|
978
|
-8.0%
|
-5.8%
|
-2.2%
|
DIAGNOSTICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
31
|
|
16
|
93.8%
|
*
|
**
|
|
|
59
|
|
46
|
28.3%
|
47.8%
|
-19.5%
|
WW
|
|
31
|
|
16
|
93.8%
|
*
|
**
|
|
|
59
|
|
46
|
28.3%
|
47.8%
|
-19.5%
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,364
|
|
1,321
|
3.3%
|
3.3%
|
-
|
|
|
2,756
|
|
2,630
|
4.8%
|
4.8%
|
-
|
Intl
|
|
991
|
|
1,009
|
-1.8%
|
0.2%
|
-2.0%
|
|
|
1,940
|
|
2,028
|
-4.3%
|
-0.5%
|
-3.8%
|
WW
|
|
2,355
|
|
2,330
|
1.1%
|
2.0%
|
-0.9%
|
|
|
4,696
|
|
4,658
|
0.8%
|
2.4%
|
-1.6%
|
HIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
197
|
|
193
|
2.1%
|
2.1%
|
-
|
|
|
400
|
|
383
|
4.4%
|
4.4%
|
-
|
Intl
|
|
152
|
|
143
|
6.3%
|
9.6%
|
-3.3%
|
|
|
291
|
|
286
|
1.7%
|
6.5%
|
-4.8%
|
WW
|
|
349
|
|
336
|
3.9%
|
5.3%
|
-1.4%
|
|
|
691
|
|
669
|
3.3%
|
5.3%
|
-2.0%
|
KNEES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
229
|
|
222
|
3.2%
|
3.2%
|
-
|
|
|
473
|
|
448
|
5.6%
|
5.6%
|
-
|
Intl
|
|
156
|
|
150
|
4.0%
|
6.7%
|
-2.7%
|
|
|
301
|
|
300
|
0.3%
|
4.4%
|
-4.1%
|
WW
|
|
385
|
|
372
|
3.5%
|
4.6%
|
-1.1%
|
|
|
774
|
|
748
|
3.5%
|
5.1%
|
-1.6%
|
TRAUMA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
381
|
|
351
|
8.5%
|
8.5%
|
-
|
|
|
762
|
|
715
|
6.6%
|
6.6%
|
-
|
Intl
|
|
255
|
|
270
|
-5.6%
|
-3.8%
|
-1.8%
|
|
|
516
|
|
562
|
-8.2%
|
-4.4%
|
-3.8%
|
WW
|
|
636
|
|
621
|
2.4%
|
3.2%
|
-0.8%
|
|
|
1,278
|
|
1,277
|
0.1%
|
1.8%
|
-1.7%
|
SPINE &
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
557
|
|
555
|
0.4%
|
0.4%
|
-
|
|
|
1,121
|
|
1,084
|
3.4%
|
3.4%
|
-
|
Intl
|
|
428
|
|
446
|
-4.0%
|
-2.5%
|
-1.5%
|
|
|
832
|
|
880
|
-5.5%
|
-2.2%
|
-3.3%
|
WW
|
|
985
|
|
1,001
|
-1.6%
|
-0.9%
|
-0.7%
|
|
|
1,953
|
|
1,964
|
-0.6%
|
0.9%
|
-1.5%
|
SURGERY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,020
|
|
1,000
|
2.0%
|
2.0%
|
-
|
|
|
2,001
|
|
1,960
|
2.1%
|
2.1%
|
-
|
Intl
|
|
1,377
|
|
1,328
|
3.7%
|
6.4%
|
-2.7%
|
|
|
2,624
|
|
2,624
|
0.0%
|
4.4%
|
-4.4%
|
WW
|
|
2,397
|
|
2,328
|
3.0%
|
4.6%
|
-1.6%
|
|
|
4,625
|
|
4,584
|
0.9%
|
3.4%
|
-2.5%
|
ADVANCED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
389
|
|
360
|
8.1%
|
8.1%
|
-
|
|
|
741
|
|
689
|
7.5%
|
7.5%
|
-
|
Intl
|
|
520
|
|
480
|
8.3%
|
11.0%
|
-2.7%
|
|
|
984
|
|
921
|
6.8%
|
11.3%
|
-4.5%
|
WW
|
|
909
|
|
840
|
8.2%
|
9.7%
|
-1.5%
|
|
|
1,725
|
|
1,610
|
7.1%
|
9.7%
|
-2.6%
|
GENERAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
421
|
|
423
|
-0.5%
|
-0.5%
|
-
|
|
|
840
|
|
845
|
-0.6%
|
-0.6%
|
-
|
Intl
|
|
706
|
|
696
|
1.4%
|
3.9%
|
-2.5%
|
|
|
1,357
|
|
1,407
|
-3.6%
|
0.5%
|
-4.1%
|
WW
|
|
1,127
|
|
1,119
|
0.7%
|
2.3%
|
-1.6%
|
|
|
2,197
|
|
2,252
|
-2.4%
|
0.2%
|
-2.6%
|
SPECIALTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
210
|
|
217
|
-3.2%
|
-3.2%
|
-
|
|
|
420
|
|
426
|
-1.4%
|
-1.4%
|
-
|
Intl
|
|
151
|
|
152
|
-0.7%
|
2.8%
|
-3.5%
|
|
|
283
|
|
296
|
-4.4%
|
1.0%
|
-5.4%
|
WW
|
|
361
|
|
369
|
-2.2%
|
-0.7%
|
-1.5%
|
|
|
703
|
|
722
|
-2.6%
|
-0.4%
|
-2.2%
|
VISION
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
248
|
|
243
|
2.1%
|
2.1%
|
-
|
|
|
490
|
|
496
|
-1.2%
|
-1.2%
|
-
|
Intl
|
|
437
|
|
403
|
8.4%
|
8.1%
|
0.3%
|
|
|
835
|
|
781
|
6.9%
|
8.9%
|
-2.0%
|
WW
|
|
685
|
|
646
|
6.0%
|
5.8%
|
0.2%
|
|
|
1,325
|
|
1,277
|
3.8%
|
5.0%
|
-1.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3,044
|
|
3,013
|
1.0%
|
1.0%
|
-
|
|
|
6,070
|
|
5,975
|
1.6%
|
1.6%
|
-
|
Intl
|
|
3,365
|
|
3,345
|
0.6%
|
2.6%
|
-2.0%
|
|
|
6,448
|
|
6,641
|
-2.9%
|
0.8%
|
-3.7%
|
WW
|
|
$
6,409
|
|
6,358
|
0.8%
|
1.8%
|
-1.0%
|
|
|
$
12,518
|
|
12,616
|
-0.8%
|
1.2%
|
-2.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Percentage greater
than 100%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
** Not
meaningful
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Operational
growth excludes the effect of translational currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3) Reported as U.S.
sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4) Prior year
amounts have been reclassified to conform to current year product
disclosure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2016-second-quarter-results-300300542.html
SOURCE Johnson & Johnson